Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Claessens

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Anticancer Research|November 1, 1991
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic miceL F Massuger, O C Boerman, F H Corstens, et al.
Diabetologia|November 23, 2019
Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetesLaura A Claessens, Joris Wesselius, Menno van Lummel, et al.
Kidney International|May 3, 2014
Shifting paradigms in eligibility criteria for live kidney donation: a systematic reviewAli R Ahmadi, Jeffrey A Lafranca, Laura A Claessens, et al.
Nuclear Medicine Communications|September 30, 1998
Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99TcmW C Buijs, W J Oyen, E T Dams, et al.
European Journal of Nuclear Medicine|November 1, 1996
Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infectionC J van der Laken, O C Boerman, W J Oyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1990
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibodyL F Massuger, P Kenemans, R A Claessens, et al.
European Journal of Nuclear Medicine|November 1, 1995
Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental modelC J van der Laken, O C Boerman, W J Oyen, et al.
Cell Reports|January 27, 2021
Global non-covalent SUMO interaction networks reveal SUMO-dependent stabilization of the non-homologous end joining complexRomán González-Prieto, Karolin Eifler-Olivi, Laura A Claessens, et al.
Nuclear Medicine Communications|July 1, 1991
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancerL F Massuger, R A Claessens, P Kenemans, et al.
Journal of the National Cancer Institute|June 16, 1993
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2J G Tibben, O C Boerman, R A Claessens, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Anticancer Research|November 1, 1991
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic miceL F Massuger, O C Boerman, F H Corstens, et al.
Diabetologia|November 23, 2019
Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetesLaura A Claessens, Joris Wesselius, Menno van Lummel, et al.
Kidney International|May 3, 2014
Shifting paradigms in eligibility criteria for live kidney donation: a systematic reviewAli R Ahmadi, Jeffrey A Lafranca, Laura A Claessens, et al.
Nuclear Medicine Communications|September 30, 1998
Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99TcmW C Buijs, W J Oyen, E T Dams, et al.
European Journal of Nuclear Medicine|November 1, 1996
Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infectionC J van der Laken, O C Boerman, W J Oyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1990
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibodyL F Massuger, P Kenemans, R A Claessens, et al.
European Journal of Nuclear Medicine|November 1, 1995
Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental modelC J van der Laken, O C Boerman, W J Oyen, et al.
Cell Reports|January 27, 2021
Global non-covalent SUMO interaction networks reveal SUMO-dependent stabilization of the non-homologous end joining complexRomán González-Prieto, Karolin Eifler-Olivi, Laura A Claessens, et al.
Nuclear Medicine Communications|July 1, 1991
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancerL F Massuger, R A Claessens, P Kenemans, et al.
Journal of the National Cancer Institute|June 16, 1993
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2J G Tibben, O C Boerman, R A Claessens, et al.
Pageof 12